Table 2.
Treatment characteristics
| Characteristics | All Patients (N = 18) n (%) |
|---|---|
| Size of LN metastases, cm (median, (range)) | 1.95 (0.8, 6.2) |
| GTV volume, cm3 (median, (range)) | 8.4 (0.7, 67.8) |
| PTV volumes, cm3 (median, (range)) | 34.8 (6.5, 162.2) |
| SBRT dose (BED10 Equivalent)a | |
| 60 Gy/8 (105 Gy) | 1 (5.6) |
| 50 Gy/10 (75 Gy) | 2 (11.1) |
| 40 Gy/5 (72 Gy) | 5 (27.8) |
| 35 Gy/5 (59.5 Gy) | 8 (44.4) |
| 31 Gy/4 (55 Gy) | 1 (5.6) |
| 33 Gy/5 (54.8 Gy) | 1 (5.6) |
| Prescribed BED10, Gy (median, (range)) | 59.5 (54.8, 105) |
| D95b BED10, Gy (median, (range)) | 56.6 (29.8, 72.0) |
| D95 BED10 > 70 Gy | 4 (22.2) |
| D95 BED10 > 50 Gy | 12 (66.7) |
| PTV V100, % | |
| Mean ± SD | 78.6 ± 22.4 |
| Median (Range) | 90.0 (21.0, 95.2) |
| PTV V95, % | |
| Mean ± SD | 87.5 ± 14.7 |
| Median (Range) | 95.6 (60.4, 100) |
| PTV V90, % | |
| Mean ± SD | 91.7 ± 10.8 |
| Median (Range) | 97.8 (67.6, 100) |
aBED10: Biological Equivalent Dose assuming α/β of 10
bD95: Minimum dose to 95% of PTV